Relationships Between GLP-2 and Markers of Bone Turnover Following Feeding

NCT ID: NCT01531907

Last Updated: 2019-02-15

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 19 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2011-09-30
• Study Completion Date: 2014-07-31

Brief Summary

This study has been designed to study differences bone turnover in relation to glucagon-like peptide-2 (GLP-2) following feeding in lean and obese premenopausal women. Given the preliminary evidence that GLP-2 may act directly on osteoclasts, the investigators plan to determine whether GLP2 receptors are expressed in osteoclasts and the effect of GLP-2 on bone resorption.

Hypotheses:

1. Acute responses of GLP-2 and bone resorption markers following feeding are affected by body fat mass.

2. Serum levels of GLP-2 are lower in obese pre-menopausal women and are associated with a reduction in trabecular and/or cortical bone mass

3. GLP-2 has direct actions on osteoclast resorption via a functional receptor

Detailed Description

Study objectives:

1. To determine if differences in baseline serum levels of GLP-2 are related to differences in bone microarchitecture, structure and strength at the distal tibia and distal radius between obese and lean premenopausal females.

2. To determine whether obesity in premenopausal females influences levels of circulating GLP-2 following a standardised glucose meal with a resultant change in markers of bone formation and resorption

3. To test whether GLP-2 directly affects osteoclast function via an identifiable receptor

Conditions

Obesity

Study Design

• Observational Model Type: CASE_CONTROL
• Study Time Perspective: PROSPECTIVE

Study Groups

Obese

Premenopausal women, 25 - 40 years with BMI of ≥30kg/m2

Study visit procedures

Intervention Type: OTHER

Anthropometric measurements to include:

• Weight, height, and BMI.
• Waist and hip circumference
• Triceps skinfold thickness
• Measurement of supine abdominal thickness A baseline blood sample (15ml)is taken before receiving a standard polycal drink (75g glucose load) Three further blood samples (15 ml) will be taken, at the time points 20, 60 and 120 minutes after glucose loading. In 10 subjects (5 lean and 5 obese) we will take an additional blood sample (up to 50 ml) at baseline into heparin to grow osteoclasts in culture. Visit duration - approximately 3-4 hours.

Lean

Premenopausal women, 25 - 40 years with BMI of 18.5-24.9 kg/m2

Study visit procedures

Intervention Type: OTHER

Anthropometric measurements to include:

• Weight, height, and BMI.
• Waist and hip circumference
• Triceps skinfold thickness
• Measurement of supine abdominal thickness A baseline blood sample (15ml)is taken before receiving a standard polycal drink (75g glucose load) Three further blood samples (15 ml) will be taken, at the time points 20, 60 and 120 minutes after glucose loading. In 10 subjects (5 lean and 5 obese) we will take an additional blood sample (up to 50 ml) at baseline into heparin to grow osteoclasts in culture. Visit duration - approximately 3-4 hours.

Interventions

Study visit procedures

Anthropometric measurements to include:

• Weight, height, and BMI.
• Waist and hip circumference
• Triceps skinfold thickness
• Measurement of supine abdominal thickness A baseline blood sample (15ml)is taken before receiving a standard polycal drink (75g glucose load) Three further blood samples (15 ml) will be taken, at the time points 20, 60 and 120 minutes after glucose loading. In 10 subjects (5 lean and 5 obese) we will take an additional blood sample (up to 50 ml) at baseline into heparin to grow osteoclasts in culture. Visit duration - approximately 3-4 hours.

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Age 25-40
• Caucasian
• Premenopausal
• Able and willing to consent
• BMI either 18.5-24.9 kg/m2 or ≥30 kg/m2
• Completion 'The Effects of Obesity on Bone Structure and Strength' study REC ref 10/H1308/61
• Consented to be approached for future research studies

Exclusion Criteria

• Fracture less than twelve months prior to recruitment
• History of any long term immobilization (duration greater than three months)
• Current pregnancy or trying to conceive Pregnancy or breast feeding less than one year prior to recruitment
• Diabetes mellitus
• History of or current conditions known to affect bone metabolism, which may include:

• Diagnosed skeletal disease or osteoarthritis
• Chronic renal disease
• Acute or chronic hepatic disease
• Hyperparathyroidism or Hyperthyroidism
• Malabsorption syndromes
• Diagnosed endocrine disorders
• Diagnosed diabetes mellitus
• Clinically significant hypocalcemia or hypercalcemia
• Diagnosed restrictive eating disorder
• Current or clinically significant previous use of medications or treatment known to affect bone metabolism, for example:

• Depot medroxyprogesterone or the combined oral contraceptive pill
• Glucocorticoid therapy
• Anti-convulsant therapy
• Bone treatments (e.g. Bisphosphonates)
• Alcohol intake of greater than 21 units per week
• Athlete, defined as an individual participating in competitive sport at amateur or professional level
• Monogenic and obesity syndromes
• History of cancer within the past 5 years excluding skin cancer non melanomas

• Minimum Eligible Age: 25 Years
• Maximum Eligible Age: 40 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: Yes

Sponsors

University of Sheffield

OTHER

Sponsor Role: collaborator

Sheffield Teaching Hospitals NHS Foundation Trust

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Paul Dimitri, Dr

Role: PRINCIPAL_INVESTIGATOR

Sheffield Childrens Hospital

Locations

Academic Unit of Bone Metabolism

Sheffield, South Yorkshire, United Kingdom

Countries

United Kingdom

Other Identifiers

STH16160

Identifier Type: -

Identifier Source: org_study_id